FSLLRY-NH2 (TFA)

CAT: 0804-HY-P1260A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-P1260A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor[1].
UNSPSC
12352209
Target
Protease Activated Receptor (PAR)
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/fsllry-nh2-tfa.html
Purity
99.74
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 1.43 mg/mL (ultrasonic)
Smiles
OC1=CC=C(C=C1)C[C@@H](C(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CC2=CC=CC=C2)N)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F
Molecular Formula
C41H61F3N10O10
Molecular Weight
910.98
References & Citations
[1]Umut Ocak, et al. FSLLRY-NH2 Improves Neurological Outcome After Cardiac Arrest in Rats. Turk Neurosurg. 2020;30 (2) :244-251.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
PAR2
Citation 01
BMC Musculoskelet Disord. 2022 May 30;23 (1) :514.|Biomolecules. 2025 Feb 1;15 (2) :208.|Brain Behav Immun. 2024 Jun 12:120:403-412.|Cell Signal. 2024 Aug 20:111355.|J Immunother Cancer. 2025 Jul 13;13 (7) :e010898.|Res Sq. 2024 Sep 04.

Popular Products